05.19.25 -- Lynn Cinelli's Wake-Up Call: Pharma's Forecasting Makes CDMOs Sick

Discover how developability assessments can streamline lead candidate selection in this Abzena webinar. Learn how evaluating key attributes like manufacturability, safety, and efficacy early in drug development helps reduce risks and improve clinical success rates. Explore advanced methodologies and technologies that provide comprehensive insights, enabling better decision-making and more efficient progress toward regulatory approval. Click here to learn more.

Explore the key differences between traditional DOE and Functional DOE as Seongjin Kim demonstrates how the latter enhances bioprocess optimization through a fed-batch cell culture example.

Creating a thorough, comprehensive RFP will help a CDMO partner lay the foundation for a productive partnership, fulfill your goals, and help ensure future market success for your therapeutic.

Rethinking your company’s SOPs to reduce carbon emissions and ensure more sustainable workflows is no easy feat. The key is looking at these initiatives as a crucial, community-driven effort.

First due at the end of 2025, the act has been delayed until late 2026, which suggests key issues that many say hobble innovation will go unaddressed for longer.

Uncover how this expert approach to process transfer supports reliable, scalable commercial manufacturing in the rapidly growing biopharmaceutical market.

To address concerns about using organic solvents in the ADC process, extractables studies were conducted on a disposable chromatography column housing and two different disposable flow paths.

Learn about the development of a serum-free suspension MDCK cell line that serves as an optimal platform for isolating human influenza viruses from clinical samples and producing vaccines at scale.

Strategically optimize your upstream and downstream processes and decrease the timeline from optimization to commercial manufacturing.

Leslie Wolfe, Ph.D., and Shaunak Uplekar, Ph.D., discuss how advanced cell line development and transposase technology speed up the path to toxicology and first-in-human studies.

Consider several key strategies and technologies designed to address the analytical considerations and material flows to facilitate the rapid delivery of toxicological material.

Understand why continued research and collaboration between industry and regulatory bodies are essential to define guidelines that ensure safety and efficacy in this rapidly advancing field.

Our data-driven DoE strategies are designed to deliver higher yields, faster turnaround times, and cost-effective solutions tailored to your development goals.

From the production floor to the shipping door, your unique clinical or commercial requirements will be fulfilled at each step of the process.

Witness how bYlok® technology can drive correct heavy-light chain pairing to >95% and how you can access it via a license agreement to overcome industry-wide challenges in bispecific production.

Over the course of 30+ years we’ve invested in and developed a broad range of expertise, a full suite of lab and analytical services, advanced technology platforms and a world-class facilities network.

We excel in facilitating rapid product selection for clinical evaluation, backed by a comprehensive package designed to de-risk and scale-up later-stage development.